Three years af­ter sell­ing Ac­er­ta to As­traZeneca in $7B deal, Dave John­son is back at the helm of a biotech start­up

Three years ago Dave John­son steered Ac­er­ta to a $7 bil­lion buy­out deal with As­traZeneca, set­ting up a rel­a­tive­ly quick­ly tran­si­tion of acal­abru­ti­nib in­to the on­col­o­gy mar­ket, where it’s now sold as Calquence.

Now, John­son is back at the helm of a new biotech start­up, and he’s still in­ter­est­ed in do­ing some­thing new in the siz­zling can­cer R&D field — this time fo­cus­ing on an­ti­body-drug con­ju­gates. John­son has a $58 mil­lion A round to get start­ed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.